OLMA Olema Pharmaceuticals, Inc.

NASDAQ
$10.29

Olema Pharmaceuticals, Inc. (OLMA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with OLMA's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
6
29 transactions
Purchases
$0
0 shares
Sales
$24.9M
905,501 shares
Net activity
-$24.9M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $24.9M 29 transactions · 905,501 shares

Largest single sale: $5.7M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Harmon Cyrus Director Sell 12,500 $11.71 $146.4K 702,770 −1.7% of holding
Harmon Cyrus Director Sell 12,500 $11.58 $144.7K 715,270 −1.7% of holding
Mitchell Shawnte 2 fills CHIEF LEGAL OFFICER Sell 25,000 $24.25 $606.4K 233 −99.1% of holding
Mitchell Shawnte CHIEF LEGAL OFFICER Sell 15,000 $23.01 $345.2K None left
Harmon Cyrus Director Sell 10,000 $26.88 $268.8K 727,770 −1.4% of holding
Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. Sell 100,000 $28.73 $2.9M 139,727 −41.7% of holding
Myles David C. 2 fills CH. DISCOV. & NON-CLIN DEV OFF Sell 50,000 $28.87 $1.4M 577,764 −8% of holding
Harmon Cyrus Director Sell 3,489 $29.12 $101.6K 737,770 −0.5% of holding
Myles David C. 2 fills CH. DISCOV. & NON-CLIN DEV OFF Sell 50,000 $27.60 $1.4M 542,961 −8.4% of holding
Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. Sell 3,822 $28.01 $107.1K 239,727 −1.6% of holding
Myles David C. CH. DISCOV. & NON-CLIN DEV OFF Sell 10,000 $28.34 $283.4K 144,846 −6.5% of holding
Zojwalla Naseem Chief Medical Officer Sell 99,509 $27.66 $2.8M 4,488 −95.7% of holding
Zojwalla Naseem Chief Medical Officer Sell 100,000 $28.04 $2.8M 53,997 −64.9% of holding
Harmon Cyrus Director Sell 2,881 $28.53 $82.2K 741,259 −0.4% of holding
CLARK IAN T 3 fills Director Sell 264,800 $29.73 $7.9M 234,896 −53% of holding
Zojwalla Naseem 2 fills Chief Medical Officer Sell 70,000 $28.20 $2.0M 116,918 −37.4% of holding
Myles David C. 3 fills CH. DISCOV. & NON-CLIN DEV OFF Sell 51,000 $30.46 $1.6M 601,656 −7.8% of holding
Harmon Cyrus 2 fills Director Sell 13,086 $8.33 $109.0K 744,140 −1.7% of holding
Harmon Cyrus 2 fills Director Sell 11,914 $8.05 $95.9K 754,140 −1.6% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.